Clinically, observational studies associate oseltamivir with hyperglycemia, worsening glycemic control [26], and delayed-onset adverse events, including neuropsychiatric symptoms and metabolic disturbances, suggesting that its inhibition of Neu-1 disrupts metabolic homeostasis [26,34]. This evidence concerns the gene NEU1 and Hyperglycemia.